Get App Open
In App
Credit Cards
Open App
you are here:

Bliss GVS Pharma Ltd.

BSE: 506197 | NSE: BLISSGVS |

Represents Equity.Intra - day transactions are permissible and normal trading is done in this category
Series: EQ | ISIN: INE416D01022 | SECTOR: Pharmaceuticals & Drugs

BSE Live

Oct 07, 16:01
152.90 -1.10 (-0.71%)
Volume
AVERAGE VOLUME
5-Day
86,764
10-Day
52,746
30-Day
39,912
40,385
  • Prev. Close

    154.00

  • Open Price

    154.00

  • Bid Price (Qty.)

    0.00 (0)

  • Offer Price (Qty.)

    0.00 (0)

NSE Live

Oct 07, 15:51
152.38 -1.21 (-0.79%)
Volume
AVERAGE VOLUME
5-Day
1,238,470
10-Day
741,849
30-Day
447,522
252,748
  • Prev. Close

    153.59

  • Open Price

    153.51

  • Bid Price (Qty.)

    152.38 (3037)

  • Offer Price (Qty.)

    0.00 (0)

Company History - Bliss GVS Pharma
1984 - Bliss GVS Pharma Limited was incorporated on 11th December, as
 public limited company and promoted by Mr Gautam Ashra. The company
 operates in two segments, health care products and pharma products.
 
 2004 - Public shareholders of the company received an open offer by
 the Fedex Securities Ltd on behalf of Shri M G Wagle, Shri Gautam R
 Ashra & Shri Shibroor N Kamath.
 
 2005 - Board of directors of the company had recommended the issue of
 bonus shares of 2 shares for every 5 shares.
 
 2006 -Board of directors of the company on 9th May, 2006, had
 approved to takeover GVS Lab and to change the name of the company
 from 'Bliss Chemicals & Pharmaceuticals India Ltd' to 'Bliss GVS
 Pharma Ltd'.
 
  - Gautam Ashra, promoter director of the company, on 18th December
 2006, sold 104,200 equity shares of the company for average sale
 price of Rs. 52.02 at the exchange.
 
 -Company has changed its name from Bliss Chemicals & Pharmaceuticals
 India Ltd. to Bliss GVS Pharma Ltd.                                  
                    
                               
 2007 - The board of the company had approved on 15th Jan 2007, to
 take over GVS Labs of S N Kamath for a consideration of Rs 160
 million. The entire consideration will be paid by way of issue of
 2,666,667 shares on a preferential basis to Kamath at a price of Rs
 60 each (at a premium of Rs. 50 each). The takeover of GVS Lab was
 effective from Apr. 01, 2006.
 
 - The company had received an order of Rs. 25.00 crores for supply of
 Anti malarial Drugs for African Countries on November 2007.
 
 - The company set up its new manufacturing unit for tablets, dry
 syrup, oral suspension and suppository pessaries in the existing
 manufacturing facility at Palghar in Maharashtra.
 
 2008 - Members at the extra ordinary general meeting of the company
 had approved split of shares of face Value of Rs 10 each into face
 value of Rs 1 each.
 
 -The company had fixed 18th March 2008 as the record date for the
 split of the equity shares of the company. The equity shares of face
 value Rs. 10 each will be sub divided in to face value of Rs. 1
 each.
 
 -The Company has issued Bonus Shares in the Ratio of 3:5.
 
 2009
 
 -Company has received an Award from Pharmexcil
 
 -Company successfully completed its 25th year of operations.
 
 2010
 
 -Company has signed a Joint Venture Agreement with Kuwait 
 
 -Mr. S N. Kamath, Promoter & Managing Director of the company has
 received a National Award -2009 from Government of India in
 recognition outstanding performance Entrepreneurship under Medium
 Enterprises.
 
 -Registered Office of the Company has been shifted from 6/29-A, Udit
 Mittal Industry, Andheri Kurla Road, Andheri - East, Mumbai - 400 059
 to 102, Hyde Park, Sakivihar Road, Andheri - East, Mumbai - 400 072
 
 2011
 
 -Bliss GVS Pharma Ltd recommended of 30% Dividend i.e. Rs. 0.30 per
 equity share
 
 2012
 
 -Company has acquired 70% management stake in the Company M/s.
 Kremoint Pharma Private Limited
 
 2013
 -Bliss GVS Pharma Ltd recommended a dividend of 40%.
 -Bliss GVS receives recognition for its Research & Development Lab
 from the Department of Scientific & Industrial Research (DSIR),
 Government of India.
 
 2014
 -Bliss GVS is named in Moneylife magazine's 'Wealth Creators
 2004-2013' list, an annual study of companies that have created the
 maximum wealth for investors over the past 10 years.
 -Bliss GVS Wins - Outstanding Exports Award.
 
 2015
 -Bliss GVS Pharma wins Healthcare Services contract in Kenya
 
 2016
 -Bliss GVS Pharma arm wins $111 mn contract from Kenyan firm.